Expectations for Efficacy and Duration of Response With Systemic Atopic Dermatitis Treatments
Panelists discuss treatment expectations for newer systemic agents, highlighting data on efficacy onset and persistence, including rapid improvement in pruritus with dupilumab by week 2 (SOLO trials), early Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI)-75 improvement with lebrikizumab by week 2 to 4 (ADvocate trials), and EASI-75 improvement with tralokinumab by week 4 (ECZTRA 6 trial), emphasizing the importance of setting realistic expectations with patients and caregivers regarding the onset of action and duration of treatment.
Video content above is prompted by the following:
6. Let’s shift now to treatment expectations. What are the data about efficacy onset and persistence when considering these newer systemic agents?
a. How do you set expectations with patients starting on systemic treatment and their caregivers in terms of onset of action and duration of treatment?
b. Dupilumab in the SOLO trials showed improvement on Peak Pruritus Numerical Rating Scale score at week 2 (in adults).
c. Lebrikizumab in the ADvocate trials showed some IGA improvement at week 4 and some EASI-75 improvement at week 2.
d. Tralokinumab in the ECZTRA 6 trial showed some EASI-75 improvement at 4 weeks (in adolescents).
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
